bemfola
gedeon richter plc. - follitropinas alfa - anovuliacija - lytiniai hormonai ir moduliatoriai lytinių organų sistemos, - in adult women:anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift);follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. klinikinių tyrimų metu šie pacientai buvo apibrėžta endogeninio serumas lh lygis < 1. 2 tv / l. in adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.
ganirelix gedeon richter
chemical works of gedeon richter plc. (gedeon richter plc.) - ganirelix acetate - reproductive techniques, assisted; ovulation induction; infertility, female - hipofizės ir hipotalaminiai hormonai ir analogai - prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).
reseligo
zentiva k.s. - goserelinas - implantas užpildytame švirkšte - 3,6 mg - goserelin
algonad
zentiva k.s. - goserelinas - implantas užpildytame švirkšte - 10,8 mg - goserelin
firmagon
ferring pharmaceuticals a/s - degareliksas - prostatos navikai - endokrininė terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatos navikai - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
orgovyx
accord healthcare s.l.u. - relugolix - prostatos navikai - endokrininė terapija - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
camcevi
accord healthcare s.l.u. - leuprorelin mesilate - prostatos navikai - endokrininė terapija - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
xanderla
teva b.v. - goserelinas - implantas užpildytame švirkšte - 3,6 mg - goserelin
goserelin teva
teva b.v. - goserelinas - implantas užpildytame švirkšte - 10,8 mg - goserelin